# OnCo record non-hodgkin-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/non-hodgkin-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "non-hodgkin-lymphoma" ;
  schema:name "Non-Hodgkin lymphoma (all types)"@en ;
  schema:alternateName "Non-Hodgkin Lymphoma"@en, "NHL"@en, "Non-Hodgkin's lymphoma"@en, "Lymphoma (non-Hodgkin)"@en, "Lymphoma"@en, "Mature B-cell neoplasms"@en, "Mature T-cell and NK-cell neoplasms"@en, "B-cell lymphoma"@en, "T-cell lymphoma"@en, "NK-cell lymphoma"@en, "Lymphatic cancer"@en, "Cancer of the lymph glands"@en, "C82"@en, "C83"@en, "C84"@en, "C85"@en, "C86"@en ;
  schema:description "Non-Hodgkin lymphoma is not one disease but a family of more than sixty cancers of the lymphocytes, the white blood cells of the immune system. About 95 per cent come from B cells and the rest from T or NK cells; some grow over years and are watched, others grow over weeks and are treated to cure. The family is the map; the subtype is the disease, and the subtype is what decides the treatment."@en ;
  schema:url <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  schema:dateModified "2026-09-29"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Non-Hodgkin_lymphoma> ;
  schema:citation <https://www.cancer.gov/types/lymphoma>, <https://doi.org/10.3322/caac.21660>, <https://lymphoma-action.org.uk/information-and-support/support-you/helpline-services>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/questions-ask-your-medical-team-about-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/cancer-related-fatigue>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you>, <https://www.maggies.org/support-and-information/>, <https://www.nhs.uk/conditions/non-hodgkin-lymphoma/>, <https://www.nhs.uk/conditions/non-hodgkin-lymphoma/symptoms/>, <https://www.nhs.uk/conditions/non-hodgkin-lymphoma/treatment/>, <https://www.macmillan.org.uk/cancer-information-and-support/lymphoma>, <https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin-lymphoma>, <https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/living-with>, <https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/getting-diagnosed/tests-diagnose>, <https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/treatment/follow-up>, <https://www.nice.org.uk/guidance/ng52>, <https://www.nice.org.uk/guidance/ng47>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/lymphoma-staging>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/biopsy>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/ct-and-petct-scan>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/waiting-test-and-scan-results>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/your-medical-team-mdt>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/clinical-trials-lymphoma-trialslink/taking-part-clinical>, <https://lymphoma-action.org.uk/information-and-support/relationships-family-friends/caring-someone-who-has-lymphoma>, <https://www.nhs.uk/social-care-and-support/support-and-benefits-for-carers/carer-assessments/>, <https://www.nhs.uk/nhs-services/urgent-and-emergency-care-services/when-to-use-111/>, <https://www.nhs.uk/nhs-services/urgent-and-emergency-care-services/when-to-call-999/>, <https://www.nhs.uk/conditions/sepsis/>, <https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/metastatic-spinal-cord-compression>, <https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/superior-vena-cava-obstruction>, <https://www.nice.org.uk/guidance/ng234>, <https://doi.org/10.1038/s41375-022-01620-2>, <https://doi.org/10.1182/blood.2022015851>, <https://doi.org/10.1038/bjc.2015.94>, <https://doi.org/10.1200/JCO.2013.54.8800>, <https://seer.cancer.gov/statfacts/html/nhl.html>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/non-hodgkin-lymphoma>, <https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq>, <https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq>, <https://lymphoma-action.org.uk/types-lymphoma>, <https://lymphoma.org/understanding-lymphoma/aboutlymphoma/>, <https://doi.org/10.3322/caac.21660>, <https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer>, <https://lymphoma-action.org.uk/>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/non-hodgkin-lymphoma> ;
  onco:tag "heme", "umbrella" ;
  onco:related <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/burkitt-lymphoma/>, <https://onco.cc/cancers/waldenstrom/>, <https://onco.cc/cancers/primary-cns-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/hiv-associated-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/biomarkers/bcl2-rearrangement/>, <https://onco.cc/biomarkers/double-hit-rearrangement/>, <https://onco.cc/biomarkers/myc-bcl2-double-expressor/>, <https://onco.cc/biomarkers/cd79b-itam-mutation/>, <https://onco.cc/biomarkers/ezh2-y646-mutation/>, <https://onco.cc/biomarkers/btk-c481s/>, <https://onco.cc/biomarkers/bcl2-g101v/>, <https://onco.cc/biomarkers/rhoa-g17v/>, <https://onco.cc/biomarkers/pd-ligand-9p24-alteration/>, <https://onco.cc/biomarkers/ig-tcr-clonality/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/high-grade-b-cell-lymphoma-myc-bcl2/>, <https://onco.cc/cancers/t-cell-histiocyte-rich-large-b-cell-lymphoma/>, <https://onco.cc/cancers/primary-testicular-lymphoma/>, <https://onco.cc/cancers/mycosis-fungoides/>, <https://onco.cc/cancers/extranodal-nk-t-cell-lymphoma/>, <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/ideas/lymphoma-ev-genetic-subtype-directed-first-line/>, <https://onco.cc/ideas/lymphoma-ev-ctdna-instead-of-the-interim-scan/>, <https://onco.cc/ideas/lymphoma-ev-radiotherapy-free-early-hodgkin/>, <https://onco.cc/ideas/lymphoma-ev-fixed-duration-chemotherapy-free-first-line/>, <https://onco.cc/ideas/lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas/>, <https://onco.cc/ideas/lymphoma-ev-manufacturing-time-as-a-trial-endpoint/>, <https://onco.cc/ideas/lymphoma-ev-the-drugs-that-cure-and-the-places-without-them/>, <https://onco.cc/ideas/lymphoma-ev-late-effects-of-the-treatments-given-now/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/clonality-testing/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/cytogenetics-fish/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/terms/ngs/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/btk/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/cd79b/>, <https://onco.cc/targets/cd22/>, <https://onco.cc/targets/cd38/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/cd47/>, <https://onco.cc/targets/ccr4/>, <https://onco.cc/targets/cd52/>, <https://onco.cc/targets/syk/>, <https://onco.cc/targets/plcg2/>, <https://onco.cc/targets/prkcb/>, <https://onco.cc/targets/card11/>, <https://onco.cc/targets/myd88/>, <https://onco.cc/targets/mcl1/>, <https://onco.cc/targets/bim/>, <https://onco.cc/targets/bcl6/>, <https://onco.cc/targets/myc-gene/>, <https://onco.cc/targets/ezh2/>, <https://onco.cc/targets/crebbp/>, <https://onco.cc/targets/ep300/>, <https://onco.cc/targets/kmt2d/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/cdkn2a/>, <https://onco.cc/targets/jak1/>, <https://onco.cc/targets/jak2/>, <https://onco.cc/targets/jak3/>, <https://onco.cc/targets/stat3/>, <https://onco.cc/targets/stat5/>, <https://onco.cc/targets/stat6/>, <https://onco.cc/targets/socs1/>, <https://onco.cc/targets/ciita/>, <https://onco.cc/targets/rhoa/>, <https://onco.cc/targets/tet2/>, <https://onco.cc/targets/dnmt3a/>, <https://onco.cc/targets/fyn/>, <https://onco.cc/targets/b2m/>, <https://onco.cc/targets/cd58/>, <https://onco.cc/targets/malt1/>, <https://onco.cc/targets/bcl10/>, <https://onco.cc/targets/birc3/>, <https://onco.cc/targets/tnfaip3/>, <https://onco.cc/targets/ccnd1/>, <https://onco.cc/targets/ccnd3/>, <https://onco.cc/targets/tcf3/>, <https://onco.cc/targets/id3/>, <https://onco.cc/targets/notch1/>, <https://onco.cc/targets/notch2/>, <https://onco.cc/targets/irf4/>, <https://onco.cc/targets/vav1/>, <https://onco.cc/targets/plcg1/>, <https://onco.cc/targets/atm/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/brentuximab-vedotin/> ;
  onco:institutions <https://onco.cc/institutions/lymphoma-action/>, <https://onco.cc/institutions/blood-cancer-uk/>, <https://onco.cc/institutions/anthony-nolan/> ;
  onco:pathways <https://onco.cc/pathways/germinal-centre-reaction/>, <https://onco.cc/pathways/bcr-signalling/>, <https://onco.cc/pathways/inflammation-nfkb/>, <https://onco.cc/pathways/apoptosis-bcl2/>, <https://onco.cc/pathways/myc/>, <https://onco.cc/pathways/jak-stat/>, <https://onco.cc/pathways/epigenetic-reprogramming/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/cd47-sirpa/>, <https://onco.cc/pathways/oncogenic-viruses/>, <https://onco.cc/pathways/antigen-presentation-immunoediting/>, <https://onco.cc/pathways/tumor-microenvironment/>, <https://onco.cc/pathways/resistance-routes-map/>, <https://onco.cc/pathways/clonal-evolution/>, <https://onco.cc/pathways/transcription-addiction/> ;
  onco:terms <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/lymphoma-tx-watch-and-wait/>, <https://onco.cc/terms/lymphoma-tx-tumour-lysis/>, <https://onco.cc/terms/lymphoma-tx-hepatitis-b-reactivation/>, <https://onco.cc/terms/lymphoma-tx-pjp-and-infection-prophylaxis/>, <https://onco.cc/terms/lymphoma-tx-immunoglobulin-replacement/>, <https://onco.cc/terms/lymphoma-tx-crs-icans/>, <https://onco.cc/terms/lymphoma-tx-fertility-preservation/>, <https://onco.cc/terms/lymphoma-tx-uk-versus-us/>, <https://onco.cc/terms/lymphoma-tx-uk-access/>, <https://onco.cc/terms/lymphoma-tx-failed-and-negative/>, <https://onco.cc/terms/lymphoma-tx-pod24/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/terms/lymphoma-tx-car-t-pathway/>, <https://onco.cc/terms/lymphoma-tx-bispecific-step-up/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/terms/lymphoma-tx-maintenance/>, <https://onco.cc/terms/lymphoma-tx-cns-prophylaxis/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/central-venous-access/>, <https://onco.cc/terms/hypogammaglobulinaemia/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/lymphoma-decision-watch-and-wait/>, <https://onco.cc/terms/lymphoma-decision-transplant-or-car-t/>, <https://onco.cc/terms/lymphoma-decision-beacopp-or-abvd/>, <https://onco.cc/terms/lymphoma-decision-fertility-timing/>, <https://onco.cc/terms/lymphoma-decision-trial/>, <https://onco.cc/terms/lymphoma-decision-local-or-car-t-centre/>, <https://onco.cc/terms/lymphoma-living-fatigue/>, <https://onco.cc/terms/lymphoma-living-hodgkin-survivorship-screening/>, <https://onco.cc/terms/lymphoma-living-infection-years-after/>, <https://onco.cc/terms/lymphoma-living-vaccinations/>, <https://onco.cc/terms/lymphoma-living-scanxiety-and-surveillance/>, <https://onco.cc/terms/lymphoma-living-returning-to-work/>, <https://onco.cc/terms/lymphoma-living-indolent-lymphoma/>, <https://onco.cc/terms/watchful-waiting/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/tumor-lysis-syndrome/>, <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/cardiotoxicity/>, <https://onco.cc/terms/deauville/>, <https://onco.cc/terms/lymphoma-bio-germinal-centre/>, <https://onco.cc/terms/lymphoma-bio-cell-of-origin-in-practice/>, <https://onco.cc/terms/lymphoma-bio-lymphgen/>, <https://onco.cc/terms/lymphoma-bio-antigen-escape/>, <https://onco.cc/terms/lymphoma-bio-lineage-antigen-cost/>, <https://onco.cc/terms/lymphoma-bio-ebv-latency/>, <https://onco.cc/terms/lymphoma-bio-htlv1/>, <https://onco.cc/terms/lymphoma-bio-hodgkin-microenvironment/>, <https://onco.cc/terms/lymphoma-bio-transformation/>, <https://onco.cc/terms/cell-of-origin/>, <https://onco.cc/terms/plasma-ebv-dna/>, <https://onco.cc/terms/flipi/>, <https://onco.cc/terms/fish/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/cytogenetics/>, <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/gene-amplification/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/cross-resistance/>, <https://onco.cc/terms/lymphoma-classification-2022/>, <https://onco.cc/terms/lymphoma-b-versus-t-cell/>, <https://onco.cc/terms/lymphoma-indolent-versus-aggressive/>, <https://onco.cc/terms/lymphoma-nodal-versus-extranodal/>, <https://onco.cc/terms/lymphoma-transformation/>, <https://onco.cc/terms/lymphoma-pit-score/>, <https://onco.cc/terms/lymphoma-htlv-1/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/ipi-score/>, <https://onco.cc/terms/mipi/>, <https://onco.cc/terms/lymphoma-type/>, <https://onco.cc/terms/ebv-term/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/terms/double-hit-lymphoma/>, <https://onco.cc/terms/autologous-transplant/>, <https://onco.cc/terms/maintenance-therapy/> ;
  onco:trials <https://onco.cc/trials/nct03844048/>, <https://onco.cc/trials/nct04002297/>, <https://onco.cc/trials/nct06230224/>, <https://onco.cc/trials/nct05947851/>, <https://onco.cc/trials/nct06084936/>, <https://onco.cc/trials/nct05645107/>, <https://onco.cc/trials/nct07582432/>, <https://onco.cc/trials/nct06082102/>, <https://onco.cc/trials/nct06947967/>, <https://onco.cc/trials/nct06522737/>, <https://onco.cc/trials/flyer/>, <https://onco.cc/trials/calgb-50303/>, <https://onco.cc/trials/goya/>, <https://onco.cc/trials/remarc/>, <https://onco.cc/trials/polargo/>, <https://onco.cc/trials/juliet/>, <https://onco.cc/trials/transcend-nhl-001/>, <https://onco.cc/trials/prima-follicular/>, <https://onco.cc/trials/ielsg-19/>, <https://onco.cc/trials/trog-99-03/>, <https://onco.cc/trials/elara/>, <https://onco.cc/trials/rosewood/>, <https://onco.cc/trials/shine/>, <https://onco.cc/trials/enrich/>, <https://onco.cc/trials/lyma/>, <https://onco.cc/trials/jcog9801/>, <https://onco.cc/trials/smile-enktl/>, <https://onco.cc/trials/polar-bear/>, <https://onco.cc/trials/arched/>, <https://onco.cc/trials/prima-cns/>, <https://onco.cc/trials/fortplus/>, <https://onco.cc/trials/mosun-lbt-fl/>, <https://onco.cc/trials/mosun-len-mzl/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-tumor-heterogeneity/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/>, <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-global-access/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-negative-results/>, <https://onco.cc/bottlenecks/b-dormancy-mrd/> ;
  onco:pipeline <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/obecabtagene-autoleucel/>, <https://onco.cc/drugs/tqb3702/>, <https://onco.cc/drugs/stp938/>, <https://onco.cc/ideas/lymphoma-ev-genetic-subtype-directed-first-line/>, <https://onco.cc/ideas/lymphoma-ev-ctdna-instead-of-the-interim-scan/>, <https://onco.cc/ideas/lymphoma-ev-radiotherapy-free-early-hodgkin/>, <https://onco.cc/ideas/lymphoma-ev-fixed-duration-chemotherapy-free-first-line/>, <https://onco.cc/ideas/lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas/>, <https://onco.cc/ideas/lymphoma-ev-manufacturing-time-as-a-trial-endpoint/>, <https://onco.cc/ideas/lymphoma-ev-the-drugs-that-cure-and-the-places-without-them/>, <https://onco.cc/ideas/lymphoma-ev-late-effects-of-the-treatments-given-now/> ;
  onco:standardOfCare <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/terms/lymphoma-type/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/lymphoma-tx-watch-and-wait/>, <https://onco.cc/terms/lymphoma-tx-hepatitis-b-reactivation/>, <https://onco.cc/terms/lymphoma-tx-fertility-preservation/>, <https://onco.cc/terms/lymphoma-tx-tumour-lysis/>, <https://onco.cc/terms/lymphoma-tx-hepatitis-b-reactivation/>, <https://onco.cc/terms/lymphoma-tx-pjp-and-infection-prophylaxis/>, <https://onco.cc/terms/lymphoma-tx-immunoglobulin-replacement/>, <https://onco.cc/terms/lymphoma-tx-crs-icans/>, <https://onco.cc/terms/lymphoma-tx-fertility-preservation/>, <https://onco.cc/drugs/rasburicase/>, <https://onco.cc/drugs/tocilizumab/>, <https://onco.cc/drugs/human-normal-immunoglobulin/>, <https://onco.cc/terms/lymphoma-tx-uk-versus-us/>, <https://onco.cc/terms/lymphoma-tx-uk-access/>, <https://onco.cc/trials/swog-s1826/>, <https://onco.cc/trials/hd21/>, <https://onco.cc/trials/polarix/>, <https://onco.cc/trials/triangle/>, <https://onco.cc/terms/lymphoma-tx-failed-and-negative/>, <https://onco.cc/trials/belinda/>, <https://onco.cc/trials/gallium/>, <https://onco.cc/terms/lymphoma-tx-cns-prophylaxis/>, <https://onco.cc/terms/lymphoma-tx-maintenance/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/> .